Rocket Pharmaceuticals, Inc.

NasdaqGM:RCKT Stock Report

Market Cap: US$1.1b

Rocket Pharmaceuticals Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGM:RCKT Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
21 Nov 24SellUS$144,782Gaurav ShahIndividual11,091US$13.05
21 Nov 24SellUS$15,338Martin WilsonIndividual1,175US$13.05
21 Nov 24SellUS$15,978John MilitelloIndividual1,224US$13.05
21 Nov 24SellUS$59,892Kinnari PatelIndividual4,588US$13.05
31 Oct 24SellUS$15,245John MilitelloIndividual917US$16.63
31 Oct 24SellUS$51,205Mark WhiteIndividual3,080US$16.63
16 Aug 24SellUS$73,812Kinnari PatelIndividual3,989US$18.50
16 Aug 24SellUS$19,004Martin WilsonIndividual1,027US$18.50
16 Aug 24SellUS$178,564Gaurav ShahIndividual9,650US$18.50
16 Aug 24SellUS$19,688John MilitelloIndividual1,064US$18.50
22 Jul 24SellUS$18,688John MilitelloIndividual812US$23.02
08 Jul 24SellUS$61,715Mark WhiteIndividual3,026US$20.40
16 May 24SellUS$24,471Martin WilsonIndividual1,048US$23.35
16 May 24SellUS$25,195John MilitelloIndividual1,079US$23.35
16 May 24SellUS$94,474Kinnari PatelIndividual4,046US$23.35
16 May 24SellUS$228,597Gaurav ShahIndividual9,790US$23.35
22 Apr 24SellUS$19,051John MilitelloIndividual833US$22.87
15 Apr 24SellUS$240,520David SouthwellIndividual10,000US$24.05
08 Apr 24SellUS$308,763Mark WhiteIndividual12,532US$24.64
21 Mar 24SellUS$69,979John MilitelloIndividual2,490US$28.10
21 Mar 24SellUS$7,790,943Simran Investment Group LlcCompany274,000US$28.43
29 Feb 24SellUS$120,257Martin WilsonIndividual4,100US$29.33
16 Feb 24SellUS$604,876Gaurav ShahIndividual20,272US$29.84
16 Feb 24SellUS$96,615John MilitelloIndividual3,238US$29.84
16 Feb 24SellUS$106,701Martin WilsonIndividual3,576US$29.84
16 Feb 24SellUS$212,805Kinnari PatelIndividual7,132US$29.84
22 Jan 24SellUS$17,356John MilitelloIndividual638US$27.20

Insider Trading Volume

Insider Buying: RCKT insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of RCKT?
Owner TypeNumber of SharesOwnership Percentage
Private Companies104,9270.106%
Individual Insiders2,224,3222.25%
Hedge Funds18,188,45718.4%
Institutions78,486,28079.3%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 84.65% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
20%
RTW Investments, LP
18,188,457US$228.4m2.83%3.32%
12.3%
Wellington Management Group LLP
11,242,144US$141.2m22.8%0.02%
6.99%
BlackRock, Inc.
6,370,721US$80.0m2.88%no data
6.07%
The Vanguard Group, Inc.
5,536,940US$69.5m-4.68%no data
4.93%
Westfield Capital Management Company, L.P.
4,493,833US$56.4m3.83%0.25%
4.52%
Maverick Capital, Ltd.
4,118,672US$51.7m4.85%0.95%
3.52%
T. Rowe Price Group, Inc.
3,207,781US$40.3m1.21%no data
3.4%
State Street Global Advisors, Inc.
3,102,022US$39.0m11.6%no data
2.36%
Citadel Advisors LLC
2,148,093US$27.0m-23.8%0.03%
2.08%
Janus Henderson Group plc
1,897,340US$23.8m-35%0.01%
1.77%
Geode Capital Management, LLC
1,617,866US$20.3m0.89%no data
1.63%
Frazier Life Sciences Management, LP
1,485,630US$18.7m-4.84%0.73%
1.61%
Tavistock Life Sciences
1,466,051US$18.4m0%1.3%
1.52%
Pictet Asset Management Limited
1,386,705US$17.4m13.1%0.02%
1.32%
Millennium Management LLC
1,202,495US$15.1m1,040%0.01%
1.22%
Gaurav Shah
1,113,566US$14.0m-0.99%no data
1.21%
Novo Holdings A/S
1,100,000US$13.8m0%0.01%
1.21%
Cowen Inc,Private Banking and Investment Banking Investments
1,100,000US$13.8m0%0.39%
1.17%
BioImpact Capital LLC
1,066,373US$13.4m0%2.33%
1.06%
Franklin Resources, Inc.
969,547US$12.2m-13.2%no data
1.02%
Perceptive Advisors LLC
931,851US$11.7m-25.3%0.27%
1%
Dimensional Fund Advisors LP
912,605US$11.5m-3.55%no data
0.97%
Baron Capital Group, Inc.
884,341US$11.1m-9.7%0.03%
0.89%
Russell Investment Management, LLC
812,310US$10.2m19.9%0.01%
0.89%
Medical Strategy GmbH, Asset Management Arm
808,816US$10.2m0%0.63%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 03:13
End of Day Share Price 2025/01/03 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Rocket Pharmaceuticals, Inc. is covered by 25 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason ZemanskyBofA Global Research
Gregory HarrisonBofA Global Research
Yun ZhongBTIG